What is the recommended management for a healthcare worker after a percutaneous needle‑stick injury from a source positive for hepatitis B surface antigen and/or HIV, for workers who are fully hepatitis‑B vaccinated versus those who have not been vaccinated?

Management of Needlestick Injury from HBsAg-Positive and/or HIV-Positive Sources

For healthcare workers with documented hepatitis B immunity (anti-HBs ≥10 mIU/mL), no treatment is required regardless of source status; for unvaccinated workers exposed to HBsAg-positive blood, administer HBIG 0.06 mL/kg IM plus the first hepatitis B vaccine dose at separate sites within 24 hours, and for HIV-positive exposures, initiate antiretroviral post-exposure prophylaxis within 72 hours for all workers regardless of vaccination status. 1, 2, 3

Immediate Actions (Within Minutes to 1 Hour)

• Wash the puncture site thoroughly with soap and water without squeezing or applying pressure—caustic agents such as bleach should never be applied. 1, 4
• If blood contacts eyes, nose, or mouth, flush immediately with clean water or saline. 4
• Report the incident to your supervisor within 1 hour and document the exact time of injury, device type, depth of penetration, blood visibility, and source patient information. 2, 4
• Never recap, bend, or break the contaminated needle. 4

Source Patient Testing (Within 1–2 Hours)

• Test the source patient immediately for HBsAg, HIV antibody (or antigen/antibody combination), and hepatitis C antibody. 1, 4
• Consider rapid HIV testing to expedite post-exposure prophylaxis decisions. 4
• Do not test discarded needles or syringes for viral contamination—results are unreliable. 4

Baseline Testing of Exposed Healthcare Worker

• Obtain baseline serology before starting any prophylaxis: HIV antibody or antigen/antibody combination, HBsAg, anti-HBs, anti-HBc, hepatitis C antibody, and liver function tests (ALT). 1, 4
• Document hepatitis B vaccination history and prior immune response. 1, 3

---

Hepatitis B Management Based on Vaccination Status

Scenario 1: Fully Vaccinated with Documented Immunity (anti-HBs ≥10 mIU/mL)

• No post-exposure treatment, serologic testing, or additional vaccination is required, regardless of whether the source is HBsAg-positive. 1, 3
• Documented immunity provides complete protection even years after vaccination. 3

Scenario 2: Unvaccinated or Incompletely Vaccinated

When Source is HBsAg-Positive:

• Administer HBIG 0.06 mL/kg intramuscularly as soon as possible (ideally within 24 hours, but effective up to 7 days). 1, 2, 3, 5
• Simultaneously administer the first dose of hepatitis B vaccine at a separate anatomic site (e.g., opposite deltoid). 1, 2, 3, 5
• Complete the full 3-dose vaccine series at 0,1, and 6 months. 1, 2, 3
• HBIG effectiveness declines markedly after 7 days post-percutaneous exposure. 1, 3

When Source is HBsAg-Negative:

• No HBIG is required; initiate the hepatitis B vaccine series alone. 3

When Source HBsAg Status is Unknown:

• Begin the hepatitis B vaccine series immediately (first dose within 24 hours). 1, 3
• HBIG is not indicated unless the source is later identified as high-risk for HBV. 3

Scenario 3: Vaccinated but Immunity Status Unknown

When Source is HBsAg-Positive:

• Draw blood immediately for anti-HBs testing, but do not wait for results. 1, 3
• Administer HBIG 0.06 mL/kg IM plus one hepatitis B vaccine booster dose at a separate site immediately. 1, 3
• If subsequent testing shows anti-HBs ≥10 mIU/mL, no further treatment is needed; if <10 mIU/mL, the HBIG and booster were appropriate. 1, 3
• Perform follow-up anti-HBs testing 4–6 months after HBIG administration to avoid detecting passively transferred antibodies. 1, 2, 3

When Source HBsAg Status is Unknown:

• Test anti-HBs immediately; if <10 mIU/mL, give one vaccine booster dose and retest 1–2 months later. 1
• If anti-HBs ≥10 mIU/mL, no treatment is required. 1

Scenario 4: Documented Non-Responder (anti-HBs <10 mIU/mL After Complete Series)

When Source is HBsAg-Positive:

• If non-responder to one 3-dose series: give HBIG 0.06 mL/kg immediately plus either a second 3-dose vaccine series or a second HBIG dose one month later. 1, 3
• If non-responder to two complete 3-dose series (six total doses): give HBIG 0.06 mL/kg immediately and a second HBIG dose one month later; no additional vaccination is indicated. 1, 3
• Counsel the worker that they remain susceptible and will require HBIG for any future HBsAg-positive exposures. 3

When Source is HBsAg-Negative:

• No treatment is required. 1, 3

---

HIV Post-Exposure Prophylaxis (All Workers, Regardless of Vaccination Status)

Indications and Timing

• Initiate HIV PEP immediately for percutaneous injuries involving blood or potentially infectious fluids (semen, vaginal secretions, CSF, synovial, pleural, peritoneal, or amniotic fluid) from an HIV-positive or status-unknown source. 4
• HIV PEP must be started within 72 hours of exposure; effectiveness declines sharply after this window. 2, 4
• Do not delay PEP while awaiting source HIV test results if the exposure is substantial. 2, 4

Preferred Regimen

• The preferred regimen is bictegravir/emtricitabine/tenofovir alafenamide (single tablet once daily) for 28 days. 4
• Completing the full 28-day course is essential—stopping early eliminates protection. 4

Monitoring During PEP

• Evaluate the worker within 72 hours of starting PEP and monitor for drug toxicity every 2 weeks with complete blood count and renal/hepatic function tests. 4
• Drug-related adverse events occur in approximately 88.6% of recipients but most complete the regimen. 6

HIV Transmission Risk Context

• The baseline percutaneous transmission risk from HIV-infected blood is approximately 0.3% (3 per 1,000 exposures). 4, 7
• Mucous membrane exposure carries a risk of approximately 0.09%. 7

---

Hepatitis C Management (All Workers)

• No post-exposure prophylaxis exists for hepatitis C; early identification through baseline and follow-up testing is the primary strategy. 1, 4
• The average transmission risk after needlestick from an HCV-positive source is approximately 1.8%. 4

---

Follow-Up Testing Schedule

HIV Testing

• Perform HIV antibody or antigen/antibody testing at baseline, 6 weeks, 3 months, and 6 months post-exposure. 1, 4
• If the source is confirmed HIV-negative with no clinical AIDS signs, baseline testing and further follow-up of the worker are generally unnecessary. 4

Hepatitis B Testing

• For workers who received hepatitis B vaccine without HBIG: test anti-HBs 1–2 months after the final vaccine dose. 1, 3, 4
• For workers who received HBIG: defer anti-HBs testing until 4–6 months after HBIG administration to avoid detecting passively transferred antibodies. 1, 2, 3
• Protective immunity is defined as anti-HBs ≥10 mIU/mL. 1, 3

Hepatitis C Testing

• Obtain baseline anti-HCV antibody and ALT at exposure. 4
• Repeat anti-HCV antibody and ALT testing at 4–6 months. 4
• If earlier diagnosis is desired, perform HCV RNA testing at 4–6 weeks post-exposure. 4

---

Precautions During Follow-Up Period

• Healthcare workers do not need to modify patient-care duties after exposure to HBV, HCV, or HIV; no special precautions are required to prevent secondary transmission. 4
• Use barrier protection during sexual activity and do not donate blood, plasma, organs, tissue, or semen during the follow-up period. 4

---

Critical Pitfalls to Avoid

• Never delay HBIG beyond 7 days for percutaneous HBV exposures—effectiveness declines markedly after this window. 1, 3
• Do not withhold HBIG solely because more than 24 hours have passed; the 24-hour recommendation is for optimal efficacy, not a contraindication. 3
• Never delay HIV PEP beyond 72 hours—effectiveness drops dramatically after this window. 2, 4
• Do not assume immunity without documented serologic testing (anti-HBs ≥10 mIU/mL); verbal history is insufficient. 3
• Never squeeze the wound or apply caustic agents such as bleach—these provide no benefit and may cause harm. 4
• Do not give more than six total doses of hepatitis B vaccine to documented non-responders; switch to HBIG-only strategy for future exposures. 3

---

Transmission Risk Context

• Hepatitis B transmission risk from HBeAg-positive blood is approximately 30% without prophylaxis—about 100-fold higher than HIV risk. 4, 7
• Combined HBIG and vaccine prophylaxis is highly effective in preventing HBV transmission when administered promptly. 2, 8
• Zero seroconversions have been documented in multiple cohorts when appropriate post-exposure prophylaxis protocols are followed. 8, 6